Background: In DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–
Thrombolysis in Myocardial Infarction 58), the sodium-glucose cotransporter 2 inhibitor …

Importance Additional treatments are needed for heart failure with reduced ejection fraction
(HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment …

Background Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have been shown to
reduce the risk of incident heart failure hospitalization in individuals with type 2 diabetes …

Background In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2
(SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose …

OBJECTIVE The sodium–glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of
cardiovascular mortality and worsening heart failure in the Dapagliflozin and Prevention of …

Background: Sodium glucose transporter-2 inhibitors reduce the risk of major adverse
cardiovascular events (MACE) in patients with type 2 diabetes mellitus and a history of …

Background: Patients with type 2 diabetes mellitus (T2DM) are at increased risk of
developing heart failure. Sodium-glucose cotransporter-2 inhibitors reduce the risk of …

Background: Outcome trials in patients with type 2 diabetes mellitus have demonstrated
reduced hospitalizations for heart failure (HF) with sodium-glucose co-transporter-2 …

Aims To investigate cardiovascular (CV) safety and event rates for dapagliflozin versus other
glucose‐lowering drugs (GLDs) in a real‐world type 2 diabetes population after applying the …

Background The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–
glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is …